Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 3
2005 4
2006 4
2007 4
2008 10
2009 8
2010 13
2011 13
2012 12
2013 11
2014 16
2015 14
2016 17
2017 15
2018 15
2019 10
2020 19
2021 17
2022 24
2023 23
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of patients with benzodiazepine receptor agonist-related psychiatric disorders and over-the-counter drug-related psychiatric disorders before and after the COVID-19 pandemic: Changes in psychosocial characteristics and types of abused drugs.
Usami T, Okita K, Shimane T, Matsumoto T. Usami T, et al. Among authors: matsumoto t. Neuropsychopharmacol Rep. 2024 Apr 15. doi: 10.1002/npr2.12440. Online ahead of print. Neuropsychopharmacol Rep. 2024. PMID: 38622878 Free article.
Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).
Arai H, Tsuda T, Sunakawa Y, Shimokawa M, Akiyoshi K, Tokunaga S, Shoji H, Kunieda K, Kotaka M, Matsumoto T, Nagata Y, Mizukami T, Mizuki F, Danenberg KD, Boku N, Nakajima TE. Arai H, et al. Among authors: matsumoto t. Cancer Med. 2024 Apr;13(7):e7107. doi: 10.1002/cam4.7107. Cancer Med. 2024. PMID: 38591098 Free PMC article. Clinical Trial.
Risk and protective factors for early dropout from telephone monitoring for individuals with drug convictions in community mental health centers in Japan.
Tsutsumi S, Takano A, Usami T, Kumakura Y, Kanazawa Y, Takebayashi T, Sugiyama D, Matsumoto T. Tsutsumi S, et al. Among authors: matsumoto t. J Subst Use Addict Treat. 2024 Mar 15;162:209347. doi: 10.1016/j.josat.2024.209347. Online ahead of print. J Subst Use Addict Treat. 2024. PMID: 38494050 Free article.
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.
Matsumoto T, Yamamoto Y, Kotaka M, Masuishi T, Tsuji Y, Shoji H, Hirata K, Tsuduki T, Makiyama A, Izawa N, Takahashi N, Tsuda M, Yasui H, Ohta T, Kito Y, Otsu S, Hironaka S, Yamazaki K, Boku N, Hyodo I, Yoshimura K, Muro K. Matsumoto T, et al. Target Oncol. 2024 Mar;19(2):181-190. doi: 10.1007/s11523-024-01043-2. Epub 2024 Mar 1. Target Oncol. 2024. PMID: 38427280 Free PMC article. Clinical Trial.
[The Science of Drug Addiction].
Matsumoto T. Matsumoto T. Brain Nerve. 2024 Jan;76(1):81-87. doi: 10.11477/mf.1416202562. Brain Nerve. 2024. PMID: 38191144 Japanese.
Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G).
Kito Y, Kawakami H, Mitani S, Nishina S, Matsumoto T, Tsuzuki T, Shinohara Y, Shimokawa H, Kumanishi R, Ohta T, Katsuya H, Kawakami T, Nishina T, Hasegawa H, Akiyoshi K, Chiba Y, Yamazaki K, Hironaka S, Muro K. Kito Y, et al. Among authors: matsumoto t. Oncologist. 2024 Mar 4;29(3):e330-e336. doi: 10.1093/oncolo/oyad296. Oncologist. 2024. PMID: 37950903 Free PMC article.
240 results